coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Cissbury Integrated Care PCN, Worthing · Health Inequalities Profile

    PCN U01092 · NHS Surrey and Sussex Integrated Care Board; NHS Sussex Integrated Care Board · 4 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    49,060

    Registered population

    59.9% aged 18–64

    23.0%

    Aged 65+

    ICB 21.9% · England 17.9%

    8.9%

    Ethnic minority (non-White)

    4.1% Asian · England 9.6%

    6.2%

    In IMD quintile 1

    ICB 9.2% · England 21.0%

    ~2,895

    Core20 residents (est.)

    Resident basis; registered basis ~3,053 · see page 3

    8,485

    Hypertension register

    +1.97% in 3 yrs · England +5.60%

    788

    SMI register

    49.2% of Worthing's

    905

    COPD register

    Reviews -1.65% in 3 yrs

    Forecast to 2030

    9,027

    Hypertension patients, 2030

    +542 on today

    67.1%

    QRISK ≥20% on statins, 2030

    +5.63pp over 3 yrs

    5.7%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    53.8%
    High-risk lipid therapy and elderly BP lag England.

    Despite +11.7% three-year growth, QRISK ≥ 20% lipid therapy (53.8% vs 63.6% in England) and aged 80+ BP control (73.4% vs 81.2%) trail national.

    16
    Sixteen of 25 three-year changes trail England.

    Reviews fell over 2023 to 2025 for heart failure (-2.3%), psychosis alcohol (-3.5 pp) and asthma (-1.2%, leaving about 1,200 asthma patients unreviewed).

    96.7%
    Early immunisations exceed 95.0% target before age-five dip.

    At 24 months, 6-in-1 (96.7%) and MMR1 (95.6%) beat the 95.0% target, though age-five 4-in-1 booster (87.9%) and MMR2 (88.7%) fall below.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Patients aged 65+ reach 23.0% alongside 70 care homes across the catchment

    CISSBURY INTEGRATED CARE PCN has a registered population of 49,060 patients. Patients aged 65+ account for 23.0% (11,286 patients), compared with 22.1% in Worthing, 21.9% in NHS Sussex Integrated Care Board, and 17.9% in England. Those aged 18-64 represent 59.9% (Worthing 60.6%; NHS Sussex Integrated Care Board 60.5%; England 62.7%), while patients aged 0-17 comprise 17.1% (Worthing 17.4%; NHS Sussex Integrated Care Board 17.7%; England 19.6%). Census estimates record White ethnicity at 91.1% (England 81.1%), with an ethnic minority share of 8.9%.

    Age profile

    0–1717.1%
    18–6459.9%
    65+23.0%

    65+: ICB 21.9%, England 17.9%

    Ethnicity

    White91.1%
    Asian4.1%
    Mixed2.5%
    Black1.2%
    Other1.1%

    Older people · falls rows are Worthing local-authority (LA) data, not PCN

    MeasureLocalSouth EastEnglandPeriod
    Falls admissions, 65+, per 100,000 (Worthing LA)2,4902,0181,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)73.8%82.2%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)57.6%57.8%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Worthing LA)1,4809819552024/25
    Falls deaths, all ages, per 100,000 (Worthing LA)15.814.014.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 deprivation is 6.2% overall, concentrating heavily in two PCN practices

    The PCN has an average IMD decile of 5.7, with 6.2% of registered patients in the Core20 cohort, above Worthing (4.4%) but below NHS Sussex Integrated Care Board (9.2%) and England (21.0%). Core20 patients concentrate in Strand Medical Group (7.83% share; 1,235 estimated patients) and Worthing Medical Group (7.39% share; 1,496 estimated patients), followed by Selden Medical Centre (3.57%; 322 estimated patients) and Cornerways Surgery (0.0%). Practice estimates sum to 3,053 patients compared with 2,895 estimated residents across 3 decile-2 LSOAs, reflecting differing population bases.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Strand Medical7.8% · 1,235 patients
    Worthing Medical7.4% · 1,496 patients
    Selden3.6% · 322 patients
    Cornerways0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    788

    SMI register

    1.58% recorded prevalence

    329

    Learning disability register

    0.66% recorded prevalence

    70

    Care homes, 1,781 beds

    In the PCN catchment

    9.0%

    Provide unpaid care

    Worthing, Census 2021

    Recorded severe mental illness includes 788 patients (1.6% vs England 1.0%), and learning disability includes 329 patients (0.7% vs England 0.6%), representing 49.2% and 38.6% of Worthing's registers respectively, alongside 70 catchment care homes (1,781 beds, occupancy unconfirmed). Recorded SMI and learning disability prevalence above England may indicate high local support requirements across primary care.

    Severe mental illness: physical health checks

    Severe mental illness prevalence is 1.6% (England 1.0%). Over 2023 to 2025, BMI recording fell 1.0 pp to 79.9% (England +5.1 pp) and alcohol checks fell 3.5 pp to 76.2% (England +5.4 pp), with Strand Medical Group at 65.5% for.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    8,485

    Hypertension register

    +1.97%

    Register growth, 3 yrs

    Worthing +3.32% · England +5.60%

    +5.35pp

    BP control, under 80

    ≤140/90 · −0.62pp aged 80+

    +542

    More patients by 2030

    Forecast 9,027 (17.73%)

    Hypertension case-finding and control

    Hypertension prevalence is 17.1% (8,485 patients), above England (15.2%) and NHS Sussex Integrated Care Board (16.3%) though below Worthing (17.4%). While 90.2% had a recent blood pressure check, treated-to-target achievement is 65.2% (Worthing 66.0%, England 70.3%). Blood pressure control in patients aged 80 and over is 73.4% (England 81.2%), falling 0.8% over 2023 to 2025 (England +2.2%). Control for patients aged under 80 reached 64.5% after +9.1% growth over 2023 to 2025 (England +3.2%), trailing England (67.8%). Lagging blood pressure control among older patients suggests scope to review treatment regimens.

    Lipids and statins

    Despite +11.7% growth over 2023 to 2025 (England +6.2%), lipid-lowering therapy for QRISK ≥ 20% patients is 53.8%, trailing Worthing (57.8%) and England (63.6%). Statin treatment for patients with diabetes and cardiovascular disease is 76.3% (Worthing 79.3%, England 84.4%). Lower uptake than national benchmarks suggests potential to recall eligible patients for lipid therapy.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202696,021£2.10£2.42£1.86£201,644
    Cardiovascular (all), 2025132,372£2.81£3.32£3.33£371,965

    In 2026, the PCN prescribed 96,021 lipid-regulating items at £2.10 per item (Worthing 2.24 gbp, England 1.86 gbp). Across 96,021 items, the PCN spends £23,045 more than at England's unit cost, and £30,727 less than at NHS Sussex Integrated Care Board's unit cost. Unit cost differences reflect prescribing mix rather than demonstrated inefficiency.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −1.23%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +0.06%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 7.7% (3,651 patients; England 6.6%), with prescribing of 1,679 items per 1,000 aged 5-19 (England 1,488). Annual asthma reviews fell 1.2% over 2023 to 2025 (England +4.4%) to 67.0%, leaving about 1,200 patients without a recorded review, with Worthing Medical Group at 59.5%. COPD prevalence is 1.8% (905 patients; England 1.9%), where reviews fell 1.6% over 2023 to 2025 (England +2.8%) to 78.1%. Review shortfalls indicate opportunities to expand routine respiratory review capacity across practices.

    Cancer register and children's immunisation

    Cancer prevalence is 4.9% (2,418 patients; England 3.8%). In Q1 2025/26, childhood vaccination exceeds the 95.0% target at 24 months (96.7% for 6-in-1, 95.6% for MMR dose 1). At age 5, coverage falls below the 95.0% target by 7.1 pp for the 4-in-1 booster (87.9%) and by 6.3 pp for MMR dose 2 (88.7%), with a 4 pp difference between doses.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months95.1%

    England 91.0%

    6-in-1 complete primary course at 24 months96.7%

    England 92.2%

    MMR dose 1 at 24 months95.6%

    England 88.3%

    MMR dose 2 at age 588.7%

    England 82.8%

    4-in-1 pre-school booster at age 587.9%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    58.5%

    Sussex ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~1,360

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Sussex ICBEnglandNo usable stageStaged cancers
    Prostate56.6%53.2%19%1,668
    Breast86.1%85.4%23%1,400
    Bowel49.8%47.0%26%1,133
    Lung30.3%33.8%15%1,058
    Skin cancer95.3%87.8%17%698

    Across NHS Sussex ICB in 2022, 58.5% of staged cancers (4,799 of 8,209) were diagnosed at stage 1 or 2, above England (55.3%) but 16.5 pp below the 75.0% national ambition. Known-stage share was 64.3% (8,209 of 12,766), trailing England (67.0%). For CISSBURY INTEGRATED CARE PCN, cancer prevalence is 4.9% (2,418 patients; England 3.8%), while cervical screening is 69.4% (England 66.8%) but reaches 60.3% at Selden Medical Centre. Staging reflects ICB-level data rather than PCN performance, and incomplete staging coverage or small site cohorts limit direct conclusions. Screening variations across member practices may contribute to missed opportunities for early detection before specialist referral.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In July 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the 62-day referral to treatment cancer standard, trailing East Sussex Healthcare NHS Trust (67.0%), Surrey and Sussex Healthcare NHS Trust (70.0%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%), standing 19.8 pp below the 85.0% standard. Diagnostic 6-week waits reached 12.9% overall (England 23.1%), but lower gastrointestinal endoscopy saw longer waits, with colonoscopy 6-week waits at 39.3% (England 30.8%) and flexible sigmoidoscopy at 45.4% (England 32.1%). Secondary care treatment backlogs and endoscopy delays could lengthen diagnostic pathways for urgent cancer referrals.

    Pathways within standard (%)SussexEast Sussex HealthcareSurrey and Sussex HealthcareSurrey and Sussex ICBEngland
    28-day faster diagnosis (75%)74.0184.2077.7479.2979.32
    31-day treatment (96%)76.7998.1996.2090.4592.50
    62-day referral to treatment (85%)65.2067.0469.9771.5171.16
    Diagnostic waits over 6 weeks (%)SussexEast Sussex HealthcareSurrey and Sussex HealthcareEngland
    MRI5.626.4827.5321.40
    CT8.570.4818.499.92
    Echocardiography0.3921.9443.7828.48
    Colonoscopy39.350.7415.1130.83
    Gastroscopy20.020.3121.0629.02
    All 15 DM01 tests12.955.2728.5023.14
    Community services activityWest Sussex residentsSurrey and Sussex ICB
    Care contacts78,050309,615
    Referrals16,01566,930
    Patients with a contact19,77085,660

    Community services (residents of West Sussex), Jun 2026 (provisional). In June 2026, provisional community services data shows 72.7% of all contacts for Worthing borough residents (56,740 of 78,050 contacts) were with adults aged 65 and over. These figures reflect upper-tier borough resident activity rather than PCN-specific contacts. High community contact volumes among older residents underline substantial local demand for intermediate and rehabilitative support.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice phone access varies by 54.2 pp and vaccination achievement by 56.5 pp

    QOF overall achievement ranges from 92.2% at Selden Medical Centre to 98.8% at Cornerways Surgery (England 92.5%). While clinical domain scores exceed 97.0% across all practices (Worthing Medical Group 97.0%; Cornerways Surgery 100.0%), vaccination achievement spans 56.5 pp, from 33.2% at Selden Medical Centre to 89.8% at Cornerways Surgery (England 55.2%).

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Cornerways Surgery1190.096.2%77.6%96.9%
    Selden983.681.5%78.7%95.7%
    Worthing Medical1177.442.0%65.0%82.8%
    Strand Medical1177.862.0%66.1%77.5%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNWorthingAssetPCNWorthing
    Care homes (catchment)70 (1,781 beds)n/aSchools (catchment)51n/a
    Children's centres57Places of worship4248
    Libraries55Homelessness support (VCS)0no data
    Day centres (VCS)11Carers support groups (VCS)11
    Primary schools (LA maintained)1113Primary academies88
    Special schools11

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma annual review recall

    Annual asthma reviews fell 1.2% (-0.8 pp) over 2023 to 2025 (England +4.4%) to 67.0% (Worthing Medical Group 59.5%), leaving an estimated 1,205 (about 1,200) of 3,651 patients unreviewed. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    CVD lipid and hypertension escalation

    Across 8,485 hypertension patients (17.1%, modelled gap -1,013 to +67), BP control is 65.2% (England 70.3%) and 73.4% in aged 80+ (England 81.2%). QRISK ≥ 20% lipid therapy is 53.8% (England 63.6%). Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Pre-school booster and MMR2 catch-up

    In Q1 2025/26 (cohort 124), age-5 coverage trails the 95.0% target by 7.1 pp for 4-in-1 (87.9%) and 6.3 pp for MMR2 (88.7%, 4 pp below MMR1 at 92.7%), while QOF vaccination spans 56.5 pp. Low cost, quick to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Anticipatory frailty reviews (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    Targeted Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI physical check outreach (p4)SMI register with a BMI recorded in the last 12 monthsMHIS · From Harm to HopePCN
    Older hypertensive medication review (p5)Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Preschool booster recall catchup (p6)4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening uptake outreach (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Practice telephony and access review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Structured asthma annual review recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN & Practice
    Option 2 · CVD lipid and hypertension escalation (p12)Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP readingCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · Pre-school booster and MMR2 catch-up (p12)Asthma register · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 2 coverage at age 5Core20PLUS5 respiratoryPCN & Practice
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026ICB2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15